In addition to MASH, the company is evaluating denifanstat in acne and in select forms of cancer, with denifanstat being tested in a Phase III clinical trial for moderate to severe acne vulgaris and a Phase III trial for recurrent glioblastoma multiforme in combination with bevacizumab. Sagimet has a global exclusive license with TAPI for innovative forms of resmetirom API to support a fixed-dose combination program combining resmetirom with denifanstat, with a Phase 3 study planned.
Cyborg Score Rationale
Recent Phase 2b trial data showed denifanstat elicited significant fibrosis improvement in advanced MASH patients. China's regulatory approval for denifanstat for acne was accepted in December 2025. However, stock volatility and early clinical stage present execution risk.
Top Insights
Positive Phase 1 pharmacokinetic results announced Dec 18, 2025 for denifanstat-resmetirom combination in healthy adults
China regulatory approval for denifanstat (ASC40) for acne in December 2025 positions international expansion
Pipeline extends beyond MASH to acne and oncology programs including solid tumors and glioblastoma
Analyst price targets recently raised: Citizens raised target to $35 from $33, Clear Street to $37 from $29 in February 2026
Named Competitors
Resmetirom — FGF21 agonist for MASH
Obeticholic acid — FXR agonist for MASH
Pioglitazone/Vitamin E — Traditional NASH treatment options
Recent Developments
(Mar 2026) Management participating in TD Cowen, Leerink, and Citizens investor conferences
(Jan 2026) Secondary analysis presented at MASH-TAG Conference showing significant fibrosis improvement in F3 MASH patients
(Dec 2025) Positive Phase 1 PK results for denifanstat-resmetirom combination and China regulatory acceptance for acne indication
Open the full interactive Sagimet Biosciences Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.